Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports strong growth for first three quarters of 2014

Roche reports strong growth for first three quarters of 2014

16th October 2014

Roche has announced its financial results for the first three quarters of 2014, during which it generated group sales of 34.76 billion euros (27.83 billion pounds).

This represented a five percent year-on-year increase in constant exchange rate terms, with its pharmaceuticals and diagnostic divisions both experiencing growth. This allowed the firm to confirm its full-year outlook.

During the last few months, the company was able to complete its takeover of InterMune, launch a new generation of fully-automated PCR testing systems and secure US regulatory approval of the idiopathic pulmonary fibrosis drug Esbriet.

Low to mid-single digit growth in group sales is expected for the full year at constant exchange rates.

Roche chief executive officer Severin Schwan said: "Demand for our products is strong in both divisions and we are well on track to reach our full-year targets."

The company was recently named as the most sustainable healthcare company in the latest Dow Jones Sustainability Indices, underlining its commitment to corporate responsibility standards.ADNFCR-8000103-ID-801754678-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.